AJP - Heart Information on EB 2010
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 295: H69-H76, 2008. First published May 2, 2008; doi:10.1152/ajpheart.00341.2008
0363-6135/08 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
295/1/H69    most recent
00341.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Belmadani, S.
Right arrow Articles by Matrougui, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Belmadani, S.
Right arrow Articles by Matrougui, K.

Microvessel vascular smooth muscle cells contribute to collagen type I deposition through ERK1/2 MAP kinase, {alpha}3-integrin, and TGF-β1 in response to ANG II and high glucose

Souad Belmadani,1 Mourad Zerfaoui,2 Hamid A. Boulares,2 Desiree I. Palen,3 and Khalid Matrougui3

Departments of 1Physiology and 2Pharmacology, Louisiana State Univeristy Health Sciences Center, New Orleans; and 3Department of Physiology, Hypertension and Renal Center of Excellence, Tulane University, School of Medicine, Health Sciences Center, New Orleans, Louisana

Submitted 1 April 2008 ; accepted in final form 25 April 2008

This study determines that vascular smooth muscle cell (VSMC) signaling through extracellular signal-regulated kinase (ERK) 1/2-mitogen-activated protein (MAP) kinase, {alpha}3-integrin, and transforming growth factor (TGF)-β1 dictates collagen type I network induction in mesenteric resistance arteries (MRA) from Type 1 diabetic (streptozotocin) or hypertensive (HT; ANG II) mice. Isolated MRA were subjected to a pressure-passive-diameter relationship. To delineate cell types and mechanisms, cultured VSMC were prepared from MRA and stimulated with ANG II (100 nM) and high glucose (HG, 22 mM). Pressure-passive-diameter relationship reduction was associated with increased collagen type I deposition in MRA from HT and diabetic mice compared with control. Treatment of HT and diabetic mice with neutralizing TGF-β1 antibody reduced MRA stiffness and collagen type I deposition. Cultured VSMC stimulated with HG or ANG II for 5 min increased ERK1/2-MAP kinase phosphorylation, whereas a 48-h stimulation induced latent TGF-β1, {alpha}3-integrin, and collagen type 1 release in the conditioned media. TGF-β1 bioactivity and Smad2 phosphorylation were {alpha}3-integrin-dependent, since β3-integrin antibody and {alpha}3-integrin inhibitor (SB-223245, 10 µM) significantly prevented TGF-β1 bioactivity and Smad2 phosphorylation. Pretreatment of VSMC with ERK1/2-MAP kinase inhibitor (U-0126, 1 µM) reduced {alpha}3-integrin, TGF-β1, and collagen type 1 content. Additionally, {alpha}3-integrin antibody, SB-223245, TGF-β1-small-intefering RNA (siRNA), and Smad2-siRNA (40 nM) prevented collagen type I network formation in response to ANG II and HG. Together, these data provide evidence that resistance artery fibrosis in Type 1 diabetes and hypertension is a consequence of abnormal collagen type I release by VSMC and involves ERK1/2, {alpha}3-integrin, and TGF-β1 signaling. This pathway could be a potential target for overcoming small artery complications in diabetes and hypertension.

hypertension; Type 1 diabetes; extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase; transforming growth factor-β1; vascular smooth muscle cell; resistance artery



Address for reprint requests and other correspondence: K. Matrougui, Dept. of Physiology, Hypertension & Renal Center of Excellence, Tulane Univ., School of Medicine, Health Sciences Center (e-mail: kmatroug{at}tulane.edu)




This article has been cited by other articles:


Home page
HypertensionHome page
A. M. Briones, N. Rodriguez-Criado, R. Hernanz, A. B. Garcia-Redondo, R. R. Rodrigues-Diez, M. J. Alonso, J. Egido, M. Ruiz-Ortega, and M. Salaices
Atorvastatin Prevents Angiotensin II-Induced Vascular Remodeling and Oxidative Stress
Hypertension, July 1, 2009; 54(1): 142 - 149.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
E. M. de Cavanagh, M. Ferder, F. Inserra, and L. Ferder
Angiotensin II, mitochondria, cytoskeletal, and extracellular matrix connections: an integrating viewpoint
Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H550 - H558.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.